Add BrightSurf on Google Email

Lunenfeld-Tanenbaum Research Institute


Largest-ever genetic study of fibromyalgia points to a neurological origin of the disorder and opens the door to new treatments

A landmark study identifies new genetic risk factors associated with fibromyalgia syndrome, pointing to a neurological origin of the disorder. The research found substantial overlap between fibromyalgia and other conditions, suggesting shared biological mechanisms that may benefit from targeted therapies.

SourceLunenfeld-Tanenbaum Research Institute·JournalNature Medicine·TypeData/statistical analysis·DateJul 28, 2026

One of the largest psychotherapy trials in the world has implications for transforming mental health care during pregnancy and after birth

A large psychotherapy trial has demonstrated that trained nurses, midwives, and doulas can deliver effective talk therapy, significantly improving symptoms of depression and anxiety in pregnant and postpartum individuals. The study also found that online therapy is equally beneficial to in-person sessions.

SourceLunenfeld-Tanenbaum Research Institute·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateMar 3, 2025

Scientists unveils key role of “selfish DNA” in early human development

Researchers found that transposable elements, known as LINE-1, play a critical role in regulating early human development. They help organize the DNA in the cell's nucleus and ensure embryonic cells progress normally through early stages. This discovery challenges previous views of these 'selfish DNA' elements.

SourceLunenfeld-Tanenbaum Research Institute·JournalDevelopmental Cell·TypeExperimental study·DateOct 15, 2024

Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals

A landmark trial found that a widely used diabetes drug, metformin, is not effective against the most common forms of early-stage breast cancer. However, researchers discovered a potential benefit for individuals with HER2-positive breast cancer, which accounts for about 20% of all breast cancers.

SourceLunenfeld-Tanenbaum Research Institute·JournalJAMA·TypeRandomized controlled/clinical trial·DateMay 24, 2022

A new target for cancer and diabetes: A novel role for the adaptor protein p66shc in regulating glucose metabolism

Researchers have identified a novel role for the adaptor protein p66shc in regulating glucose metabolism, suggesting its potential as a therapeutic target for cancer and diabetes. Silencing p66shc enhances glucose metabolism and cell growth, indicating it may act as an energy sensor that responds to nutrient availability.

SourceLunenfeld-Tanenbaum Research Institute·JournalScience Signaling·DateFeb 13, 2014